iTeos Therapeutics (ITOS) News Today $7.68 +0.19 (+2.52%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period 5 US Longevity and Anti-aging Stocks to Watch in 2025January 24, 2025 | msn.comiTeos Therapeutics: Promising Phase 2 Data Boosts Buy Rating on Lead Asset Belrestotug CombinationJanuary 17, 2025 | markets.businessinsider.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) Short Interest Down 21.1% in DecemberiTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) saw a large drop in short interest during the month of December. As of December 31st, there was short interest totalling 1,500,000 shares, a drop of 21.1% from the December 15th total of 1,900,000 shares. Based on an average daily volume of 556,500 shares, the short-interest ratio is presently 2.7 days. Currently, 4.9% of the company's shares are short sold.January 16, 2025 | marketbeat.comiTeos Therapeutics (NASDAQ:ITOS) Earns "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $21.00 target price on shares of iTeos Therapeutics in a research report on Thursday.January 16, 2025 | marketbeat.comiTeos Therapeutics outlines business updates, strategies for 2025January 11, 2025 | markets.businessinsider.comiTeos Therapeutics' (ITOS) "Outperform" Rating Reaffirmed at WedbushWedbush reiterated an "outperform" rating and issued a $25.00 price objective on shares of iTeos Therapeutics in a report on Friday.January 10, 2025 | marketbeat.comiTeos Announces 2025 Strategic Priorities and Anticipated MilestonesJanuary 10, 2025 | markets.businessinsider.comState Street Corp Increases Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)State Street Corp increased its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 21.9% during the third quarter, according to its most recent filing with the SEC. The fund owned 1,175,353 shares of the company's stock after buying an additional 211,452 shares during the quarter. StaDecember 26, 2024 | marketbeat.comiTeos Therapeutics (NASDAQ:ITOS) Price Target Lowered to $19.00 at Wells Fargo & CompanyWells Fargo & Company cut their price objective on shares of iTeos Therapeutics from $31.00 to $19.00 and set an "overweight" rating for the company in a research report on Thursday.December 19, 2024 | marketbeat.comiTeos Therapeutics: A Perhaps Unjustified Decline To End 2024December 17, 2024 | seekingalpha.comInupadenant “deprioritised” by iTeos in favour of pipeline TIGIT therapyDecember 15, 2024 | finance.yahoo.comStrategic Focus on Belrestotug Drives Buy Rating for iTeos Therapeutics with Adjusted Price Target of $21December 14, 2024 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for iTeos Therapeutics (NASDAQ:ITOS)HC Wainwright reissued a "buy" rating and issued a $21.00 target price on shares of iTeos Therapeutics in a research note on Friday.December 13, 2024 | marketbeat.comiTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology CongressDecember 12, 2024 | globenewswire.comRA Capital Management L.P. Sells 332,548 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS)RA Capital Management L.P. lessened its holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 9.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,184,711 shares of the company's stock after selling 332,December 5, 2024 | marketbeat.comReadystate Asset Management LP Has $1.73 Million Stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS)Readystate Asset Management LP raised its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 97.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 169,819 shares of the company's stock after acquiring an adDecember 5, 2024 | marketbeat.comVestal Point Capital LP Has $10.47 Million Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)Vestal Point Capital LP trimmed its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 41.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,025,000 shares of the company's stock after selling 725,00November 29, 2024 | marketbeat.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Bought by Algert Global LLCAlgert Global LLC grew its position in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 92.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 256,139 shares of the company's stock after buying aNovember 27, 2024 | marketbeat.comiTeos to Participate in Upcoming Investor ConferencesNovember 26, 2024 | globenewswire.comMatthew Gall Acquires 5,000 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) StockNovember 20, 2024 | insidertrades.comPromising Developments and Strategic Positioning Drive Buy Rating for iTeos TherapeuticsNovember 15, 2024 | markets.businessinsider.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next YearNovember 15, 2024 | finance.yahoo.comiTeos Therapeutics' (ITOS) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $46.00 price objective on shares of iTeos Therapeutics in a research report on Friday.November 15, 2024 | marketbeat.comWedbush Predicts Stronger Earnings for iTeos TherapeuticsiTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) - Equities researchers at Wedbush boosted their FY2024 earnings per share (EPS) estimates for iTeos Therapeutics in a research note issued on Tuesday, November 12th. Wedbush analyst D. Nierengarten now anticipates that the company will post earNovember 15, 2024 | marketbeat.comiTeos Therapeutics: Potential Upside from Adenosine Program Amidst TIGIT ChallengesNovember 14, 2024 | markets.businessinsider.comiTeos Therapeutics Reports Q3 2024 Financial ResultsNovember 14, 2024 | markets.businessinsider.comStrategic Catalysts and Financial Stability Underpin Buy Rating for iTeos TherapeuticsNovember 13, 2024 | markets.businessinsider.comiTeos Reports Third Quarter 2024 Financial Results and Provides Business UpdatesNovember 12, 2024 | globenewswire.comBOXER CAPITAL, LLC Expands Stake in ITeos Therapeutics IncOctober 16, 2024 | finance.yahoo.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) Stock Position Decreased by AQR Capital Management LLCAQR Capital Management LLC trimmed its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 66.0% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 29,298 shares of the company's stock after selling 56,870 sharesOctober 16, 2024 | marketbeat.comMillennium Management LLC Decreases Stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS)Millennium Management LLC lessened its stake in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 72.7% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 241,305 shares of the company's stock after selling 641,676 sharesOctober 14, 2024 | marketbeat.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) Short Interest UpdateiTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) was the target of a significant increase in short interest in September. As of September 30th, there was short interest totalling 4,820,000 shares, an increase of 92.0% from the September 15th total of 2,510,000 shares. Based on an average daily volume of 518,700 shares, the short-interest ratio is presently 9.3 days. Currently, 17.2% of the company's stock are short sold.October 12, 2024 | marketbeat.comDimensional Fund Advisors LP Grows Stock Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)Dimensional Fund Advisors LP increased its holdings in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 14.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 908,329 shares of the compOctober 6, 2024 | marketbeat.comTANG CAPITAL MANAGEMENT LLC Acquires New Stake in ITeos Therapeutics IncSeptember 30, 2024 | finance.yahoo.com156,894 Shares in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Bought by Clearline Capital LPClearline Capital LP bought a new position in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 156,894 shares of the company's stock, valued at approximSeptember 29, 2024 | marketbeat.comRenaissance Technologies LLC Sells 157,700 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS)Renaissance Technologies LLC trimmed its position in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 22.0% in the second quarter, according to its most recent filing with the SEC. The fund owned 559,600 shares of the company's stock after selling 157,700 shares during the period. RenaissancSeptember 25, 2024 | marketbeat.comInnate Pharma S.A. (IDD.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comPiper Sandler maintains Overweight rating on iTeos Therapeutics stockSeptember 18, 2024 | uk.investing.comWedbush Weighs in on iTeos Therapeutics, Inc.'s FY2027 Earnings (NASDAQ:ITOS)iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) - Wedbush lifted their FY2027 earnings per share (EPS) estimates for shares of iTeos Therapeutics in a note issued to investors on Sunday, September 15th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($September 18, 2024 | marketbeat.comITeos Therapeutics Shares Rise on Positive Data From Lung Cancer StudySeptember 17, 2024 | marketwatch.comiTeos Therapeutics (ITOS) Receives a Buy from Piper SandlerSeptember 17, 2024 | markets.businessinsider.comiTeos Therapeutics' (ITOS) Buy Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and issued a $46.00 target price on shares of iTeos Therapeutics in a report on Monday.September 16, 2024 | marketbeat.comiTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGITSeptember 15, 2024 | seekingalpha.comBuy Rating Affirmed for iTeos Therapeutics Amid Promising Lung-201 Study OutcomesSeptember 14, 2024 | markets.businessinsider.comGSK, iTeos Lung Cancer Data Set to Reignite Hope for Drug ClassSeptember 14, 2024 | bloomberg.comiTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer PatientsSeptember 14, 2024 | globenewswire.comiTeos Therapeutics (NASDAQ:ITOS) Sees Large Volume IncreaseiTeos Therapeutics (NASDAQ:ITOS) Sees Unusually-High Trading VolumeSeptember 11, 2024 | marketbeat.comiTeos Therapeutics (NASDAQ:ITOS) Shares Up 8.2%iTeos Therapeutics (NASDAQ:ITOS) Trading 8.2% HigherSeptember 9, 2024 | marketbeat.comCandriam S.C.A. Invests $7.56 Million in iTeos Therapeutics, Inc. (NASDAQ:ITOS)Candriam S.C.A. bought a new stake in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 509,303 shares of the company's stock, valued at approximately $7,558,0September 9, 2024 | marketbeat.comiTeos Therapeutics Inc.: iTeos to Participate in Upcoming Investor ConferencesAugust 28, 2024 | finanznachrichten.de Get iTeos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITOS and its competitors with MarketBeat's FREE daily newsletter. Email Address ITOS Media Mentions By Week ITOS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ITOS News Sentiment▼0.930.74▲Average Medical News Sentiment ITOS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ITOS Articles This Week▼32▲ITOS Articles Average Week Get iTeos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITOS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies COLL News Today NTLA News Today SYRE News Today GYRE News Today ELVN News Today ZYME News Today ABCL News Today RCKT News Today ETNB News Today AVBP News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ITOS) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredTrump’s back in the oval office. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. And he says 2025 could be...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iTeos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iTeos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ITOS Stock Alerts